Abstract 114P
Background
Oesophageal fistula is a life-threatening complication that may occur during oesophageal squamous cell carcinoma treatment. Clinical evidence of established risk factors for the development of fistula is limited. This study investigated the risk factors based on clinical data.
Methods
We retrospectively reviewed clinical data of patients with locally advanced (T4) oesophageal cancer who received chemoradiotherapy or chemotherapy alone in our institute between April 2018 and May 2022. Patients were excluded if they had a fistula before treatment started. T-test, Fisher’s exact test, and logistic regression analysis were used to analyse the data.
Results
Out of 42 patients studied, 19 developed fistula. All patients received chemotherapy. In the fistula group, 11 patients received definitive concurrent radiotherapy, one received palliative radiotherapy, and seven did not receive radiotherapy. Low body mass index (BMI) was the only significant risk factor associated with fistula formation (p=0.042). There was no significant association between oesophageal stricture at baseline, type of radiotherapies, ages, performance status, serum albumin, C-reactive protein, and neutrophil- lymphocyte ratio with fistula formation. The overall survival (OS) in the fistula group was significantly shorter than in the non-fistula group (275 days vs. 447 days, P=0.014). The median survival time from the development of the fistula was 58 days.
Conclusions
In this trial, low BMI at baseline independently increased the risk of oesophageal fistula occurring after oesophageal cancer treatment. It was also identified that oesophageal fistula is associated with poor prognosis. Further prospective studies are needed to establish other risk factors to avoid this unfavourable complication.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
48P - Long-term clinical outcomes after the second metastasectomy in patients (pts) with resected metastatic colorectal cancer (mCRC)
Presenter: Songji Choi
Session: Poster viewing 02
49P - Ramucirumab beyond progression plus TAS 102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab based therapy: Final results of the phase II RE-ExPEL study
Presenter: Thorsten Goetze
Session: Poster viewing 02
50P - Linear tumor regression of rectal cancer in daily MRI during preoperative chemoradiotherapy: An insight of tumor regression velocity for personalized cancer therapy
Presenter: Sea-Won Lee
Session: Poster viewing 02
51P - Efficacy and safety of sintilimab as first-line therapy in patients with microsatellite instability-high metastatic colorectal cancer: A real-world study
Presenter: Caiyun Nie
Session: Poster viewing 02
53P - Baseline PET/CT deep radiomics signature apply for identifying bevacizumab sensitivity of RAS-mutant colorectal cancer liver metastases patients
Presenter: Wenju Chang
Session: Poster viewing 02
54P - Efficacy of total neoadjuvant therapy (TNT) in rectal cancer: A meta-analysis of randomized controlled trials
Presenter: Yakup Ergün
Session: Poster viewing 02
55P - Biodegradable and biocompatible 3D-printed scaffolds loaded with chemotherapy drugs: A new horizon for treatment of colon cancer with diffuse intraperitoneal metastasis
Presenter: Amirhosein Kefayat
Session: Poster viewing 02
56P - Clinico-pathological profile of adolescent and young adult colorectal cancer patients: Multicentre collaborative registry data from India
Presenter: Soumya Surath Panda
Session: Poster viewing 02